Naloxone hydrochloride; pentazocine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for naloxone hydrochloride; pentazocine hydrochloride and what is the scope of freedom to operate?
Naloxone hydrochloride; pentazocine hydrochloride
is the generic ingredient in two branded drugs marketed by Lupin, Sun Pharm Inds Ltd, Watson Labs, and Sanofi Aventis Us, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.Three suppliers are listed for this compound.
Summary for naloxone hydrochloride; pentazocine hydrochloride
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 2 |
| DailyMed Link: | naloxone hydrochloride; pentazocine hydrochloride at DailyMed |
Recent Clinical Trials for naloxone hydrochloride; pentazocine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute on Aging (NIA) | Phase 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
| Office of Research on Women's Health (ORWH) | Phase 1 |
See all naloxone hydrochloride; pentazocine hydrochloride clinical trials
Pharmacology for naloxone hydrochloride; pentazocine hydrochloride
| Drug Class | Opioid Antagonist Partial Opioid Agonist/Antagonist |
| Mechanism of Action | Competitive Opioid Antagonists Opioid Antagonists Partial Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for naloxone hydrochloride; pentazocine hydrochloride
US Patents and Regulatory Information for naloxone hydrochloride; pentazocine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 074736-001 | Jan 21, 1997 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm Inds Ltd | NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 075523-001 | Mar 17, 2000 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sanofi Aventis Us | TALWIN NX | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 018733-001 | Dec 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin | NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 075735-001 | Jul 11, 2001 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for naloxone hydrochloride; pentazocine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TALWIN NX | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 018733-001 | Dec 16, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
